tiprankstipranks
Trending News
More News >

Immunovant price target lowered to $35 from $51 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Immunovant (IMVT) to $35 from $51 and keeps a Buy rating on the shares. The target cut reflects the company’s data readouts in 2027, with an expected potential launch in 2028.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1